SG195568A1 - Nmda receptor antagonists for the treatment of neuropsychiatric disorders - Google Patents

Nmda receptor antagonists for the treatment of neuropsychiatric disorders Download PDF

Info

Publication number
SG195568A1
SG195568A1 SG2013077359A SG2013077359A SG195568A1 SG 195568 A1 SG195568 A1 SG 195568A1 SG 2013077359 A SG2013077359 A SG 2013077359A SG 2013077359 A SG2013077359 A SG 2013077359A SG 195568 A1 SG195568 A1 SG 195568A1
Authority
SG
Singapore
Prior art keywords
alkyl
phenyl
compound
piperazin
hydroxy
Prior art date
Application number
SG2013077359A
Other languages
English (en)
Inventor
Raymond J Dingledine
Stephen F Traynelis
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of SG195568A1 publication Critical patent/SG195568A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG2013077359A 2008-05-09 2009-05-11 Nmda receptor antagonists for the treatment of neuropsychiatric disorders SG195568A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12709808P 2008-05-09 2008-05-09

Publications (1)

Publication Number Publication Date
SG195568A1 true SG195568A1 (en) 2013-12-30

Family

ID=41265475

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013077359A SG195568A1 (en) 2008-05-09 2009-05-11 Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Country Status (16)

Country Link
US (1) US20110160223A1 (enExample)
EP (1) EP2296658A4 (enExample)
JP (1) JP2011520815A (enExample)
KR (1) KR20110016891A (enExample)
CN (1) CN102762207A (enExample)
AU (1) AU2009244082A1 (enExample)
BR (1) BRPI0912362A2 (enExample)
CA (1) CA2722776A1 (enExample)
CO (1) CO6341558A2 (enExample)
EA (1) EA020339B1 (enExample)
IL (1) IL208895A0 (enExample)
MX (1) MX2010012186A (enExample)
NZ (1) NZ589764A (enExample)
SG (1) SG195568A1 (enExample)
WO (1) WO2009137843A2 (enExample)
ZA (1) ZA201007958B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762554A (zh) 2010-02-16 2012-10-31 辉瑞大药厂 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
US8974365B2 (en) * 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
AU2014243773B2 (en) 2013-03-13 2018-12-13 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
WO2014210456A1 (en) 2013-06-28 2014-12-31 Emory University Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3204011A4 (en) * 2014-10-07 2018-06-20 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
CA2991214C (en) 2015-07-06 2024-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
US11117924B2 (en) 2015-07-06 2021-09-14 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
MA44526A (fr) 2016-04-01 2021-06-02 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
US11111266B2 (en) 2016-10-18 2021-09-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN109803656B (zh) * 2017-10-09 2021-08-31 华南农业大学 一种抗白色念珠菌的化合物及其制备方法和应用
US11981652B2 (en) 2018-03-28 2024-05-14 Emory University GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
KR102793535B1 (ko) 2018-06-27 2025-04-11 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하는 방법
JP2022504036A (ja) 2018-10-05 2022-01-13 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害を治療するためのエスケタミンの投与計画
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
CN114539129B (zh) * 2020-11-18 2023-06-09 上海中医药大学附属龙华医院 烯丙胺类双功能化合物及其用途
JP2024533182A (ja) 2021-09-02 2024-09-12 エモリー ユニバーシティー 酸性ｐＨで増強された効力を有するＮ－メチル－Ｄ－アスパラギン酸受容体のＧｌｕＮ２Ｂサブユニット選択的アンタゴニスト

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0005828B1 (de) * 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2824677A1 (de) * 1978-06-06 1979-12-20 Hoechst Ag Neue substituierte phenylpiperazinderivate und verfahren zu deren herstellung
JPS55162774A (en) * 1979-06-06 1980-12-18 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649362A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Thiocarbostyril derivative
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS579769A (en) * 1980-06-23 1982-01-19 Otsuka Pharmaceut Co Ltd 2-benzimidazolinone derivative
JPS58203968A (ja) * 1982-05-21 1983-11-28 Otsuka Pharmaceut Co Ltd イソカルボスチリル誘導体
DE3442570A1 (de) * 1984-11-22 1986-05-22 Hoechst Ag, 6230 Frankfurt Neue substituierte phenylpiperazinderivate, verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere
JPS62252783A (ja) * 1986-02-13 1987-11-04 ワ−ナ−−ランバ−ト・コンパニ− ベンズ複素環式化合物
GB9005318D0 (en) * 1990-03-09 1990-05-02 Isis Innovation Antiarrhythmic agents
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
CA2681877A1 (en) * 1997-10-31 1999-05-14 Asubio Pharma Co., Ltd. Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
WO2002028814A2 (en) * 2000-10-06 2002-04-11 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
DE10248925A1 (de) * 2002-10-15 2004-04-29 Proteosys Ag Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität
WO2004100956A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
HUP0401526A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use
AU2005277055B2 (en) * 2004-08-23 2011-03-31 Emory University Improved selection of-pH dependent compounds for in vivo therapy
JP2009500440A (ja) * 2005-07-12 2009-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 性欲障害治療用医薬組成物
TWI329641B (en) * 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
US7935706B2 (en) * 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
CN101815518B (zh) * 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂

Also Published As

Publication number Publication date
US20110160223A1 (en) 2011-06-30
CN102762207A (zh) 2012-10-31
MX2010012186A (es) 2011-02-22
EP2296658A4 (en) 2014-01-15
WO2009137843A9 (en) 2010-03-11
CO6341558A2 (es) 2011-11-21
WO2009137843A2 (en) 2009-11-12
EA020339B1 (ru) 2014-10-30
BRPI0912362A2 (pt) 2015-10-06
EA201071291A3 (ru) 2014-02-28
IL208895A0 (en) 2011-01-31
KR20110016891A (ko) 2011-02-18
JP2011520815A (ja) 2011-07-21
CA2722776A1 (en) 2009-11-12
ZA201007958B (en) 2011-07-27
AU2009244082A1 (en) 2009-11-12
EP2296658A2 (en) 2011-03-23
EA201071291A2 (ru) 2011-04-29
NZ589764A (en) 2012-10-26

Similar Documents

Publication Publication Date Title
SG195568A1 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
US20240352031A1 (en) Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto
CN101815518B (zh) 用于神经保护的nmda受体拮抗剂
CN108558831B (zh) 取代吡咯-4-烷基胺类化合物及其用途
CN112689633A (zh) 用于抑制Nav1.8的吡啶甲酰胺化合物
CN105254557A (zh) 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
EP4346818B1 (en) Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
US8680279B2 (en) Compounds for the treatment of neurological disorders
RU2387644C2 (ru) Циклопропилпиперидиновые ингибиторы транспортера глицина
AU2013203941A1 (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
US20140275060A1 (en) Compounds for the treatment of neurologic disorders
US20250073217A1 (en) Small molecule adrenoreceptor antagonists and uses thereof
AU2013203908A1 (en) Compounds for the treatment of neurologic disorders
HK40053244A (en) Pyridazinone derivative
NZ623571A (en) Dosage regimen for an s1p receptor modulator or agonist
HK1146902B (en) Nmda receptor antagonists for neuroprotection
NZ623571B2 (en) Dosage regimen for an s1p receptor modulator or agonist